Medical Update

from mdanews.orgALS TDI to Test Multiple
Sclerosis Drug in ALS
The MDA-supported ALS Therapy Development Institute (ALS-TDI) plans to launch a phase 2 clinical trial of TDI 132, a compound that modulates the immune system

Article Highlights:

The nonprofit biotech ALS Therapy Development Institute plans to launch a phase 2 trial to determine the safety and tolerability of TDI 132 — also known as fingolimod — in ALS.

Fingolimod (brand name Gilenya) is approved by the U.S. Food and Drug Administration for the treatment of multiple sclerosis. In humans, Gilenya inhibits certain immune system cells from entering the central nervous system, where they can result in damage to motor neurons.

ALS TDI reports that mice treated with TDI 132 showed positive outcomes on several disease measures.

To learn more, read the full ALS News Online article.

als.mda.org
Scott Wiebe
National Director — Outreach Services & ALS Division



World Leader in ALS Research and Services